Search

everythinglearnresearchcommunity

for

Search:↓

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

Microneedling for hair loss, with concerns about cost and conflicting information on protocols. The user is unsure about purchasing and reusing microneedling stampers.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.

Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The focus is on setting realistic expectations for these treatments.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A user tried microneedling for hair loss with a Dr. Pen at 0.8 mm and experienced bleeding, questioning if the intensity was too much. Others suggested a less aggressive approach, and one mentioned finasteride as a helpful treatment without side effects.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

Topical finasteride concentrations and application amounts are debated, with concerns that mainstream solutions may use arbitrary concentrations. A 0.25% solution with a specific application method is suggested as more appropriate than higher concentrations.

A user reported that Procerin, containing Saw Palmetto and Pumpkin seed oil, provided similar hair thickening results as finasteride but with milder side effects. They experienced reduced libido and watery ejaculations but are adjusting the dose to minimize these effects.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

The conversation discusses verteporfin as a potential hair loss treatment and questions why more precise methods aren't used to test its effectiveness in regrowing hair. Some users believe verteporfin is promising and should receive more attention, while others are skeptical about the testing methods.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.

Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.

The conversation discusses the steps for microneedling, specifically differentiating between medical needling (0.5-1.5mm) and cosmetic needling (0.3mm). It emphasizes the importance of cleaning and disinfecting before microneedling, regardless of needle length.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.